Related references
Note: Only part of the references are listed.Resistance to activated protein C in systemic lupus erythematosus patients with antiphospholipid antibodies
Juzo Matsuda et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Thrombin generation as an intermediate phenotype for venous thrombosis A proof-of-concept study
Olivier Segers et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Regulation of TFPI function by protein S
T. M. Hackeng et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus
Junzo Nojima et al.
THROMBOSIS RESEARCH (2009)
Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: A cross-over study
K. Fleischer et al.
THROMBOSIS RESEARCH (2009)
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera
Marina Marchetti et al.
BLOOD (2008)
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency
Connie Duckers et al.
BLOOD (2008)
Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va
Sinh Tran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V
Andrew J. Gale et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Increased acquired activated protein C resistance in unselected patients with hematological malignancies
H. F. S. Negaard et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia
E. Castoldi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive
Damayanthi Devineni et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va
Eva A. Norstrom et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Role of P1 residues Arg331 and Arg562 in the activated-protein-C-catalysed inactivation of factor VIIIa
Fatbardha Varfaj et al.
BIOCHEMICAL JOURNAL (2006)
Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor
TM Hackeng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation
JM Brugge et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
An underestimated combination of opposites resulting in enhanced thrombotic tendency
P Simioni et al.
BLOOD (2005)
The anticoagulant protein C pathway
B Dahlbäck et al.
FEBS LETTERS (2005)
Mechanisms for acquired activated protein C resistance in cancer patients
G Sarig et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation:: a randomized
JM Kemmeren et al.
BLOOD (2004)
Intraindividual consistency of the activated protein C resistance phenotype
A Tosetto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Phenotypic sensitivity to activated protein C in healthy families: importance of genetic components and environmental factors
C Taralunga et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations
E Castoldi et al.
BLOOD (2004)
Functional characterization of factor V-Ile359Thr:: a novel mutation associated with thrombosis
M Steen et al.
BLOOD (2004)
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women
G Tans et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Importance of protein S and phospholipid for activated protein C-mediated cleavages in factor Va
EA Norstrom et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Factor VI359T: a novel mutation associated with thrombosis and resistance to activated protein C
AD Mumford et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility
JM Soria et al.
BLOOD (2003)
Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C
AJ Gale et al.
PROTEIN SCIENCE (2002)
Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype
T Yamazaki et al.
BLOOD (2002)
Functional characterization of recombinant FV Hong Kong and FV Cambridge
E Norstrom et al.
BLOOD (2002)
Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations
M Kalafatis et al.
BLOOD (2002)
The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model
MV Kolfschoten et al.
BLOOD COAGULATION & FIBRINOLYSIS (2002)
Genetic determinants of hemostasis phenotypes in Spanish families
JC Souto et al.
CIRCULATION (2000)
Share Paper
